Skip to main content
. 2022 Feb 28;9:856064. doi: 10.3389/fmolb.2022.856064

FIGURE 4.

FIGURE 4

DFS and OS based on SIRI scores in patients with breast cancer of various molecular subtypes (NACT group). DFS and OS based on SIRI scores in patients with breast cancer of various molecular subtypes (NACT group). (A) Kaplan-Meier analysis of DFS for the SIRI of patients with luminal A breast cancer. (B) Kaplan-Meier analysis of OS for the SIRI of patients with luminal A breast cancer. (C) Kaplan-Meier analysis of DFS for the SIRI of patients with luminal B HER2-positive breast cancer. (D) Kaplan-Meier analysis of OS for the SIRI of patients with luminal B HER2-positive breast cancer. (E) Kaplan-Meier analysis of DFS for the SIRI of patients with luminal B HER2-negative breast cancer. (F) Kaplan-Meier analysis of OS for the SIRI of patients with luminal B HER2-negative breast cancer. (G) Kaplan-Meier analysis of DFS for the SIRI of patients with HER2-overexpressing breast cancer. (H) Kaplan-Meier analysis of OS for the SIRI of patients with HER2-overexpressing breast cancer. (I) Kaplan-Meier analysis of DFS for the SIRI of patients with triple-negative breast cancer. (J) Kaplan-Meier analysis of OS for the SIRI of patients with triple-negative breast cancer.